Wedelolactone Inhibits Breast Cancer-Induced Osteoclastogenesis by Decreasing Akt/mTOR Signaling

    November 2014 in “ International Journal of Oncology ”
    Chia‐Jung Hsieh, Po‐Lin Kuo, Ming‐Feng Hou, Jen‐Yu Hung, Fang‐Rong Chang, Ying-Chan Hsu, Ya‐Fang Huang, Eing‐Mei Tsai, Ya‐Ling Hsu
    TLDR Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.
    The study demonstrated that wedelolactone (WDL), a natural compound, inhibited breast cancer-induced osteoclastogenesis by targeting the Akt/mTOR signaling pathway. WDL effectively suppressed the differentiation and activity of osteoclasts derived from human CD14+ monocytes in vitro and reduced osteoclastogenesis stimulated by MDA-MB-231 breast cancer cells. It decreased the expression of macrophage colony-stimulating factor (M-CSF) in osteoblasts, reducing the interaction between osteoblasts and osteoclasts that promotes bone destruction. These findings suggested that WDL could be a potential natural agent for preventing and treating bone destruction in patients with breast cancer-related bone metastasis.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results